Mereo BioPharma Group plc Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Mereo BioPharma Group plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q3 2024.
  • Mereo BioPharma Group plc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$15M, a 130% decline year-over-year.
  • Mereo BioPharma Group plc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$45.3M.
  • Mereo BioPharma Group plc annual Net Income (Loss) Attributable to Parent for 2023 was -$29.5M, a 30.2% increase from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$45.3M -$15M -$8.47M -130% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$36.8M -$12.3M -$10.5M -600% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$26.3M -$8.95M +$3.13M +25.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$29.5M -$9.11M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 -$6.53M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$1.75M Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$12.1M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.